Sign In


Larry J. Schaaf PhD

Larry J. Schaaf PhD
DirectorCollege of Medicinelarry.schaaf@osumc.edu
1232B James Cancer Hosp & Res Inst 300 W 10th Avenue Columbus OH 43210
Phone:614-293-6851Fax: 614-293-4072
  • Experimental Therapeutics

General Research Interest

Clinical Pharmacy

Research Description

Larry J. Schaaf, PhD is Director of the Clinical Treatment Unit (CTU) at the Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. Dr. Schaaf has extensive experience in pharmacokinetics and early clinical trials and has played a key role in the development and clinical application of a number of widely used anti-cancer drugs, including irinotecan, exemestane, and epirubicin. Dr. Schaaf also manages the Clinical Trials Processing Laboratory (CTPL) which is responsible of procurement, processing, storage and shipment of the majority of correlative science specimens collected as part of phase I trials.

Transinstitutional Work

Dr. Schaaf collaborates with a number of investigators in designing the pharmacokinetic and pharmacodynamic components of clinical trials. As Director of the Clinical Trials Processing Laboratory, he insures that correlative research specimens collected at OSU but analyzed at outside institutions are properly processed, stored and shipped

Current Publications

  • Patnaik A, Papadopoulos KP, Tolcher AW, Beeram M, Urien S, Schaaf LJ, Tahiri S, Bekaii-Saab T, Lokiec FM, Rezaï K, Buchbinder APhase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer.Cancer Chemother Pharmacol in press 3/30/2013
  • Mrózek E, Layman R, Ramaswamy B, Schaaf L, Li X, Ottman S, Shapiro CLPhase II trial of exemestane in combination with fulvestrant in postmenopausal women with advanced, hormone-responsive breast cancer.Clin Breast Cancer 12(2) 151-6 4/1/2012
  • Hofmeister CC, Yang X, Pichiorri F, Chen P, Rozewski DM, Johnson AJ, Lee S, Liu Z, Garr CL, Hade EM, Ji J, Schaaf LJ, Benson DM Jr, Kraut EH, Hicks WJ, Chan KK, Chen CS, Farag SS, Grever MR, Byrd JC, Phelps MAPhase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein.J Clin Oncol 29(25) 3427-34 9/1/2011